Cargando…

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes

A 22-year-old Japanese woman consulted an endocrinologist due to persistent galactorrhea for the past 10 months. She had hyperprolacinemia and had previously been diagnosed with type 2 diabetes mellitus based on her glycohemoglobin level of 11.6%. After two months, she was admitted to our hospital a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oshige, Tamami, Nakamura, Yui, Sasaki, Yuko, Kawano, Seiko, Ohki, Tsuyoshi, Tsuruta, Munehisa, Tokubuchi, Ichiro, Nakayama, Hitomi, Yamada, Kentaro, Ashida, Kenji, Tajiri, Yuji, Nomura, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875449/ https://www.ncbi.nlm.nih.gov/pubmed/31243214 http://dx.doi.org/10.2169/internalmedicine.2755-19

Ejemplares similares

Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
por: Yamada, Kentaro, et al.
Publicado: (2015)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience
por: Cho, Kyung Rae, et al.
Publicado: (2013)

Temporal resolution of idiopathic granulomatous mastitis with resumption of bromocriptine therapy for prolactinoma
por: Bouton, Marcia E., et al.
Publicado: (2015)

Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma
por: Menon, Lakshmi P., et al.
Publicado: (2021)

Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3
por: Gobaru, Mizuki, et al.
Publicado: (2019)

Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells
por: Huang, Jinxiang, et al.
Publicado: (2017)

Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes
por: Tajiri, Yuji, et al.
Publicado: (2014)

Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats
por: Tokubuchi, Ichiro, et al.
Publicado: (2017)

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas
por: Xiao, Zhengzheng, et al.
Publicado: (2020)

Thyroid-related ophthalmopathy development in concurrence with growth hormone administration
por: Iwata, Shimpei, et al.
Publicado: (2021)

Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas: Erratum
por: Xiao, Zhengzheng, et al.
Publicado: (2022)

Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy
por: Eguchi, Hiroyuki, et al.
Publicado: (2015)

Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report
por: Nagayama, Ayako, et al.
Publicado: (2019)

Bromocriptine or cabergoline-induced cerebrospinal fluid rhinorrhea: A life-threatening complication during management of prolactinoma
por: Singh, Pratibha, et al.
Publicado: (2011)

Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma
por: Igata, Motoyuki, et al.
Publicado: (2020)

Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
por: Goto, Yuka, et al.
Publicado: (2020)

Distinct Relevance of Nightly Sleep Duration to Metabolic, Anthropometric, and Lifestyle Factors in Patients with Type 2 Diabetes
por: Nakayama, Hitomi, et al.
Publicado: (2020)

Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively
por: Tang, Chao, et al.
Publicado: (2019)

Protective effect of 3-hydroxybutyrate against endoplasmic reticulum stress-associated vascular endothelial cell damage induced by low glucose exposure
por: Soejima, Eri, et al.
Publicado: (2018)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl-xL signaling pathways
por: Xiao, Zhengzheng, et al.
Publicado: (2021)

Surrogate index for insulin sensitivity composed of factors not using glucose and insulin in Japanese patients with diabetes
por: Tajiri, Yuji, et al.
Publicado: (2011)

Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury
por: Hasuzawa, Nao, et al.
Publicado: (2021)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Treatment of Prolactinoma
por: Inder, Warrick J., et al.
Publicado: (2022)

Management of pituitary tumour apoplexy with bromocriptine in pregnancy
por: Janssen, Nina M, et al.
Publicado: (2012)

Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
por: Winkel, Jasper, et al.
Publicado: (2012)

Bromocriptine and insulin sensitivity in lean and obese subjects
por: Bahler, L, et al.
Publicado: (2016)

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Effects of tolcapone and bromocriptine on cognitive stability and flexibility
por: Cameron, Ian G. M., et al.
Publicado: (2018)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
por: Simon, Rebecca, et al.
Publicado: (2018)

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
por: Shikata, Masato, et al.
Publicado: (2020)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

Approach to the Patient With Prolactinoma
por: Auriemma, Renata S, et al.
Publicado: (2023)

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy
por: Chopra, Sandeep, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u3b5pdds9pn8hqqq83nis6igj0